Alphatec Holdings, Inc. (NASDAQ: ATEC) announced its preliminary financial results for the full-year 2024 and provided a financial outlook for the full-year 2025. The company reported that full-year 2024 total revenue grew by 27% to approximately $611 million. Surgical revenue for the full-year 2024 was in the range of $543.6 million to $544.6 million, while EOS revenue was in the range of $66.7 million to $67.2 million. The total revenue for the full-year 2024 was in the range of $610.3 million to $611.8 million.
The preliminary unaudited year-end 2024 cash balance approximated $139 million, reflecting an increase of $58 million compared to the third quarter of 2024, inclusive of $50 million in proceeds related to the term loan expansion announced with the company's third quarter 2024 financial results.
Looking ahead to 2025, the company anticipates full-year total revenue of $732 million, representing a growth of approximately 20% compared to the full-year 2024. This includes surgical revenue of approximately $657 million and approximately $75 million of EOS revenue. Additionally, the company expects adjusted EBITDA of approximately $75 million, which will contribute to positive free cash flow for the full-year 2025.
Alphatec Holdings, Inc. will report its fourth quarter and full-year 2024 financial results on February 26, 2025, after the market close and will host a live webcast on that day at 1:30 p.m. PT / 4:30 p.m. ET.
The company also announced an inducement award granted to 12 new employees (who are not executive officers) of, collectively, 26,013 restricted stock units ("RSUs") under the company's 2016 employment inducement award plan.
Alphatec Holdings, Inc. believes that non-GAAP financial measures provide investors with an additional tool for evaluating the company's core performance. The company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the same industry.
Alphatec Holdings, Inc., through its wholly-owned subsidiaries, Alphatec Spine, Inc., EOS Imaging S.A.S, and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. The company's vision is to become the standard bearer in spine.
The overall financial performance of Alphatec Holdings, Inc. demonstrates a significant increase in total revenue and provides a positive outlook for the full-year 2025, indicating potential continued growth and profitability for the company. The market has reacted to these announcements by moving the company's shares 9.8% to a price of $10.95. Check out the company's full 8-K submission here.
